Recent Posts
- Q-Vant Biosciences Collaborates with Tulane University to Develop a Promising New Oral Vaccine Adjuvant October 28, 2024
- Q-VANT and SPI Pharma Offering Broader Access to Sustainable and Scalable Pharma-grade Saponin Adjuvants October 28, 2024
- Q-Vant Biosciences Announces Positive Study Results for Its Sustainable Quillaja-Based Vaccine Adjuvant, Q-VET-S®, in Kansas State’s Classic Swine Fever Vaccine October 28, 2024